company background image
ORCHPHARMA logo

Orchid Pharma NSEI:ORCHPHARMA Stock Report

Last Price

₹1.06k

Market Cap

₹54.0b

7D

5.8%

1Y

155.7%

Updated

06 Jun, 2024

Data

Company Financials +

Orchid Pharma Limited

NSEI:ORCHPHARMA Stock Report

Market Cap: ₹54.0b

ORCHPHARMA Stock Overview

A pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India.

ORCHPHARMA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth6/6
Past Performance2/6
Financial Health6/6
Dividends0/6

Orchid Pharma Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Orchid Pharma
Historical stock prices
Current Share Price₹1,064.55
52 Week High₹1,359.95
52 Week Low₹411.00
Beta2.41
1 Month Change6.92%
3 Month Change-1.21%
1 Year Change155.66%
3 Year Change-22.33%
5 Year Changen/a
Change since IPO5,814.17%

Recent News & Updates

Orchid Pharma Limited's (NSE:ORCHPHARMA) Intrinsic Value Is Potentially 17% Below Its Share Price

May 08
Orchid Pharma Limited's (NSE:ORCHPHARMA) Intrinsic Value Is Potentially 17% Below Its Share Price

Recent updates

Orchid Pharma Limited's (NSE:ORCHPHARMA) Intrinsic Value Is Potentially 17% Below Its Share Price

May 08
Orchid Pharma Limited's (NSE:ORCHPHARMA) Intrinsic Value Is Potentially 17% Below Its Share Price

Orchid Pharma Limited's (NSE:ORCHPHARMA) P/S Is Still On The Mark Following 72% Share Price Bounce

Feb 28
Orchid Pharma Limited's (NSE:ORCHPHARMA) P/S Is Still On The Mark Following 72% Share Price Bounce

Does Orchid Pharma (NSE:ORCHPHARMA) Have A Healthy Balance Sheet?

Feb 06
Does Orchid Pharma (NSE:ORCHPHARMA) Have A Healthy Balance Sheet?

Orchid Pharma Limited (NSE:ORCHPHARMA) Looks Just Right With A 33% Price Jump

Dec 18
Orchid Pharma Limited (NSE:ORCHPHARMA) Looks Just Right With A 33% Price Jump

Shareholder Returns

ORCHPHARMAIN PharmaceuticalsIN Market
7D5.8%-0.3%-1.7%
1Y155.7%52.2%37.8%

Return vs Industry: ORCHPHARMA exceeded the Indian Pharmaceuticals industry which returned 52.2% over the past year.

Return vs Market: ORCHPHARMA exceeded the Indian Market which returned 37.8% over the past year.

Price Volatility

Is ORCHPHARMA's price volatile compared to industry and market?
ORCHPHARMA volatility
ORCHPHARMA Average Weekly Movement6.5%
Pharmaceuticals Industry Average Movement6.2%
Market Average Movement6.8%
10% most volatile stocks in IN Market9.8%
10% least volatile stocks in IN Market4.4%

Stable Share Price: ORCHPHARMA has not had significant price volatility in the past 3 months.

Volatility Over Time: ORCHPHARMA's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1992838Manish Dhanukawww.orchidpharma.com

Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India. Its active pharmaceutical ingredients product portfolio includes oral cephalosporins, injectable cephalosporins, veterinary products, and non-antibiotics. The company’s multi-therapeutic presence in anti-infectives, anti-inflammatory, central nervous system, cardiovascular segment, nutraceuticals, and other oral and sterile products, as well as offers new drug discovery systems and pharmaceutical research and development services.

Orchid Pharma Limited Fundamentals Summary

How do Orchid Pharma's earnings and revenue compare to its market cap?
ORCHPHARMA fundamental statistics
Market cap₹53.99b
Earnings (TTM)₹1.25b
Revenue (TTM)₹8.12b

43.3x

P/E Ratio

6.6x

P/S Ratio

Is ORCHPHARMA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ORCHPHARMA income statement (TTM)
Revenue₹8.12b
Cost of Revenue₹4.92b
Gross Profit₹3.20b
Other Expenses₹1.96b
Earnings₹1.25b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)24.56
Gross Margin39.44%
Net Profit Margin15.34%
Debt/Equity Ratio13.3%

How did ORCHPHARMA perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.